Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
Experimental drug aims to control debilitating muscle disease
Disease control OngoingThis global Phase 3 trial is testing whether an intravenous drug called AOC 1001 can help control symptoms of myotonic dystrophy type 1, a genetic muscle-wasting disease. About 159 adults with a confirmed diagnosis will receive either the drug or a placebo via infusion every 8 we…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Four-Year trial tests potential new treatment for debilitating muscle disease
Disease control ENROLLING_BY_INVITATIONThis study is testing the long-term safety and effectiveness of an investigational drug called del-desiran for adults with myotonic dystrophy type 1 (DM1), a genetic muscle-wasting disease. Participants who completed a previous related study will receive an intravenous infusion o…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC